Bionano Genomics

Bionano Genomics is a life sciences company that has developed a revolutionary technology called Optical Genome Mapping (OGM) for analyzing structural variations in the genome. The company's flagship product, the Saphyr system, utilizes OGM to detect various types of genomic abnormalities, including aneuploidies, deletions, duplications, translocations, inversions, and repeat expansions/contractions, with high sensitivity and accuracy.

OGM provides a comprehensive solution for structural variation analysis, offering advantages over traditional cytogenetic methods. It can detect low-cell-fraction structural variants, down to 10% variant allele fraction, and has a high throughput capacity of over 5,000 samples per year. The Saphyr system, coupled with the NxClinical Software, enables reliable and cost-effective structural variation detection for applications in cancer research, genetic disease diagnosis, and other areas of genomic medicine.

In addition to the Saphyr system, Bionano Genomics has developed other products to enhance its OGM workflow. The Stratys system, introduced in 2024, provides higher throughput capabilities for high-volume laboratories. The company has also acquired isotachophoresis technology from Purigen Biosystems, enabling automated DNA isolation through the Ionic system, addressing a bottleneck in the OGM workflow.

Bionano Genomics has made significant advancements in its computational tools, including the VIA software suite, which integrates OGM, next-generation sequencing, and microarray data for comprehensive cancer analysis. The company has also introduced AI-enhanced capabilities and automated reporting features to streamline data analysis and interpretation.

Bionano Genomics is operating as a publicly listed company, and is traded on NasdaqCM under the ticker symbol BNGO.

Key customers and partnerships

Bionano Genomics has garnered interest from a growing number of biopharma customers, who recognize the value of OGM in developing safe and innovative therapies. The company has collaborated with NVIDIA to develop a high-performance compute solution for OGM data analysis, enabling faster processing times for high-throughput systems.

Additionally, Bionano Genomics has established partnerships with academic and research institutions, such as Radboud University Medical Center in the Netherlands, where a EUR 900,000 grant was awarded to translate OGM into routine use for leukemias, solid tumors, and constitutional genetic diseases, leveraging Bionano's end-to-end workflow.